ACR Open Rheumatol
Long-term data support upadacitinib efficacy in spondyloarthritis
May 22, 2024
Through 1 year, upadacitinib showed sustained efficacy vs. placebo with no new safety findings. Findings support the continued favorable benefit-risk profile of upadacitinib for treating nr-axSpA.
- Researchers randomized patients ≥18 years diagnosed with nr-axSpA who fulfilled the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria and were receiving stable background therapy with upadacitinib 15 mg once daily or placebo for the 52-week double-blind period.
- Among 314 randomized patients, 259 completed 52 weeks of treatment. More patients receiving upadacitinib vs. placebo achieved ≥40% improvement in ASAS at week 52. Similar treatment effects were observed for the achievement of axSpA Disease Activity Score inactive disease.
- Overall, patients receiving upadacitinib vs. placebo showed greater improvement in disease activity, inflammation, pain, function, enthesitis, and QOL through 52 weeks. Adverse events were generally comparable between treatment groups.
Source:
Van den Bosch F, et al. (2024, May 15). ACR Open Rheumatol. Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/38747163/
TRENDING THIS WEEK